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We thank Dr Martinez-Martin et al. for their
interest in our article.1 In their letter, the
authors question if ‘SGLT1 has no compensa-
tory role during the inhibition of SGLT2’. We
referred to a study published by Gembardt
et al.2 in diabetic ob/ob mice with complete
pharmacological blockade of SGLT2. In con-
trast to the study published by Rieg et al.,3
Gembardt did not report an upregulation of
renal SGLT1 protein levels and differential re-
sults on the levels of SGLT1 mRNA in ob/ob
diabetic mice under complete SGLT2 block-
ade. But the observed (incomplete) 30–50%
inhibition of reabsorption by SGLT2 inhibitors
appears to be the sum of SGLT1 compensation
and residual SGLT2 activity.4 So, we agree with
the authors of the letter that our wording is
overstated and thank them for pointing this
out.
With respect to the second comment about
Table 1, we aimed to review the most import-
ant effects of SGLT2 inhibition, and due to
space constraints, we had to limit ourselves
to effects to key organs. It is correct that
SGLT2 is also expressed outside of organs
mentioned by (i.e. kidney, brain, thyroid, and
heart); we realize that the full list of all organs
that express SGLT2 contains .20 organs.5
We thank the readers Martinez-Martin,
Jimenez-Martin, and Sablon-Gonzalez for their
awareness and suggestions.
References
1. de Leeuw AE, de Boer RA. SGLT2 inhibition: cardio-
protection by treating diabetes. A translational view-
point explaining its potential salutary effects. Eur
Heart J Cardiovasc
2. Gembardt F et al. The SGLT2 inhibitor empagliflozin
ameliorates early features of diabetic nephropathy in
BTBR ob/ob type 2 diabetic mice with and without
hypertension. Am J Physiol Ren Physiol 2014;307:
F317–F325.
3. Rieg T et al. Increase in SGLT1-mediated transport
explains renal glucose reabsorption during genetic
and pharmacological SGLT2 inhibition in euglycemia.
Am J Physiol Ren Physiol 2014;306:F188–F193.
4. Lu Y, Griffen SC, Boulton DW, Leil TA. Use of sys-
tems pharmacology modeling to elucidate the oper-
ating characteristics of SGLT1 and SGLT2 in renal
glucose reabsorption in humans. Front Pharmacol
2014;5:274.
5. http://www.genecards.org/cgi-bin/carddisp.pl?gene=
SLC2A2&keywords=SGLT2 (16 May 2016).
Anne E. de Leeuw and Rudolf
A. de Boer*
University Medical Center Groningen (UMCG),
Department of Cardiology, University of
Groningen,
AB43, Hanzeplein 1, 9713GZ
Groningen, The Netherlands
*Corresponding author. Tel: +31 50 361 5340,
Fax: +31 50 361 5525, Email: r.a.de.boer@umcg.nl
Published on behalf of the European Society of Cardiology. All rights reserved. & The Author 2016. For permissions please email: journals.permissions@oup.com
doi:10.1093/ehjcvp/pvw015
European Heart Journal – Cardiovascular Pharmacotherapy (2016) 2, 257
Pharmacother 2016; :244–255.2
Downloaded from https://academic.oup.com/ehjcvp/article-abstract/2/4/257/2197186
by University Library user
on 06 December 2017
